Steven Romano, MD

Steven Romano is a seasoned pharmaceutical executive with more than 25 years of research, development and medical affairs experience across a wide range of therapeutic areas and all phases of drug development. Dr. Romano currently serves as Chief Medical Officer and Head, Research and Development, at Silence Therapeutics, a development stage biopharmaceutical company with a proprietary small interfering RNA platform, on whose board he served for the past 4 years.  

Prior to joining Silence Therapeutics, Dr. Romano was Executive Vice President and Chief Science Officer of Mallinckrodt Pharmaceuticals, overseeing development and medical programs in the areas of critical and neonatal care, immunology and rare disease.  Prior to Mallinckrodt, Dr. Romano spent 16 years at Pfizer where he held a series of senior research and development and medical roles culminating in his position as SVP, Head, Global Medicines Development, overseeing development programs across both primary and specialty care conditions. His previous roles include positions in clinical research at Eli Lilly in the neurosciences, as well as academic appointments and clinical positions at The New York Hospital-Cornell Medical Center (now Weill-Cornell Medical)

Dr. Romano is a Non-Executive Director of Evolution Research Group, a privately held site management and contract research organization focused on the execution of clinical trials across all phases of drug development. He recently completed his tenure as Chairman of the National Pharmaceutical Council, a non-profit health policy research organization, and is a past president of the International Society of CNS Trials and Methodology. 

Dr. Romano, a board-certified psychiatrist, graduated from Washington University in St. Louis with a bachelor’s degree in Biology and English literature and received his MD from the University of Missouri-Columbia School of Medicine. He completed residency training, including a chief residency at The New York Hospital-Cornell Medical Center, where he continued on the faculty of the medical school prior to joining industry.